Somewhat Positive News Coverage Somewhat Unlikely to Affect Agilent Technologies (A) Share Price

Press coverage about Agilent Technologies (NYSE:A) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agilent Technologies earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.3304292992937 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Several equities research analysts recently weighed in on the company. Goldman Sachs upgraded Agilent Technologies from a “neutral” rating to a “buy” rating in a report on Monday, April 9th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a report on Wednesday, April 4th. ValuEngine upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Robert W. Baird restated a “buy” rating and set a $76.00 target price on shares of Agilent Technologies in a report on Thursday, January 18th. Finally, Barclays restated a “buy” rating and set a $74.00 target price on shares of Agilent Technologies in a report on Monday, January 8th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Agilent Technologies has an average rating of “Buy” and a consensus price target of $72.20.

A stock traded up $0.27 during trading on Tuesday, hitting $68.44. 2,682,621 shares of the company traded hands, compared to its average volume of 2,494,343. The stock has a market capitalization of $21,673.61, a PE ratio of 29.00, a P/E/G ratio of 2.31 and a beta of 1.31. Agilent Technologies has a 1 year low of $52.68 and a 1 year high of $75.00. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.23 and a quick ratio of 2.78.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.08. Agilent Technologies had a return on equity of 17.70% and a net margin of 4.25%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the business posted $0.53 EPS. analysts anticipate that Agilent Technologies will post 2.7 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 25th. Shareholders of record on Tuesday, April 3rd will be issued a $0.149 dividend. This represents a $0.60 annualized dividend and a yield of 0.87%. The ex-dividend date is Monday, April 2nd. Agilent Technologies’s dividend payout ratio (DPR) is currently 25.42%.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 21,850 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,638,750.00. Following the completion of the sale, the chief executive officer now owns 324,687 shares in the company, valued at approximately $24,351,525. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Heidi Fields sold 5,000 shares of the stock in a transaction that occurred on Tuesday, March 27th. The stock was sold at an average price of $68.09, for a total value of $340,450.00. Following the completion of the sale, the director now owns 57,563 shares of the company’s stock, valued at approximately $3,919,464.67. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,400 shares of company stock valued at $4,809,327.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Agilent Technologies (A) Share Price” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-agilent-technologies-a-share-price.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply